Search Results

A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol.

• Authors : Wegener E; GenesisCare Lake Macquarie Private Hospital, 3 Sydney St Lake Macquarie, Gateshead, NSW, 2290, Australia. .; University of Newcastle, Callaghan, NSW, 2308, Australia. .

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/radiotherapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/pathology

• Source: BMC cancer [BMC Cancer] 2025 Feb 13; Vol. 25 (1), pp. 250. Date of Electronic Publication: 2025 Feb 13.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study.

• Authors : Bakenga A; Department of Medical Oncology and Hematology, Uganda Cancer Institute, Kampala, Uganda. .; Natukunda B

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/pathology ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/mortality

• Source: BMC cancer [BMC Cancer] 2024 Nov 14; Vol. 24 (1), pp. 1404. Date of Electronic Publication: 2024 Nov 14.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.

• Authors : Nikitas J; Department of Radiation Oncology, University of California, Los Angeles, CA, USA.; Gafita A

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/diagnostic imaging ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/pathology

• Source: Scientific reports [Sci Rep] 2024 Oct 18; Vol. 14 (1), pp. 24411. Date of Electronic Publication: 2024 Oct 18.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system.

• Authors : Wang CL; Department of Family Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/diagnosis ; Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/therapeutic use

• Source: Scientific reports [Sci Rep] 2024 Nov 18; Vol. 14 (1), pp. 28460. Date of Electronic Publication: 2024 Nov 18.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study.

• Authors : Jae Heon Kim¹; Gi Hwan Bae²; Jaehun Jung^2,3

• Source: World Journal of Men's Health. Jan2025, Vol. 43 Issue 1, p123-133. 11p.

Record details

Evaluating the Effects of Prostate Radiotherapy Intensified with Pelvic Nodal Radiotherapy and Androgen Deprivation Therapy on Myelosuppression: Single-Institution Experience.

• Authors : Katib Y; College of Medicine, Taibah University, Madinah 42353, Saudi Arabia.; Department of Radiation Oncology, McGill University Health Centre, Montreal, QC H3A 3J1, Canada.

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/radiotherapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/therapeutic use

• Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Sep 13; Vol. 31 (9), pp. 5439-5451. Date of Electronic Publication: 2024 Sep 13.Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729

Record details

A Non-Randomized Comparison of Online and In-Person Formats of the Canadian Androgen Deprivation Therapy Educational Program: Impacts on Side Effects, Bother, and Self-Efficacy.

• Authors : Walker LM; Division of Psychosocial Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 4N1, Canada.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 4N1, Canada.

Subjects: Self Efficacy* ; Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/therapeutic use ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy

• Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Aug 28; Vol. 31 (9), pp. 5040-5056. Date of Electronic Publication: 2024 Aug 28.Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729

Record details

Androgen deprivation therapy: The cure for prostate cancer or the cause of high mortality?

• Authors : Ahmed AI; Department of Medicine, Bahria Univesity of Health Sciences, Karachi, Pakistan.; Ijaz M

Subjects: Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/therapeutic use ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/mortality

• Source: Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Jul 01; Vol. 20 (5), pp. 1666-1667. Date of Electronic Publication: 2024 Sep 19.Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.

• Authors : Guo Y; Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.; Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, 518132, China.

Subjects: NF-kappa B*/NF-kappa B*/NF-kappa B*/metabolism ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/pathology

• Source: Journal of nanobiotechnology [J Nanobiotechnology] 2024 Apr 18; Vol. 22 (1), pp. 192. Date of Electronic Publication: 2024 Apr 18.Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155

Record details

Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.

• Authors : Wang B; Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Shanghai, 200032, People's Republic of China.; Shanghai Genitourinary Cancer Institute, Shanghai, China.

Subjects: Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/therapeutic use ; Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/administration & dosage ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/pathology

• Source: BMC cancer [BMC Cancer] 2024 May 25; Vol. 24 (1), pp. 643. Date of Electronic Publication: 2024 May 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details